No recent analyst price targets found for CERO.
Latest News for CERO
CERo Therapeutics Announces Clinical Update from CERTAIN-T Phase 1 CER-1236 Trial, Including Patient Undergoing Allogeneic Stem Cell Transplant Following Treatment
Fifth patient treated with CER-1236 underwent stem cell transplant following lack of response to prior therapies; Company initiates third planned cohort in ongoing Phase 1 study in hematologic malignancies
CERo Therapeutics Announces Clinical Update from CERTAIN-T Phase 1 CER-1236 Trial, Including Patient Undergoing Allogeneic Stem Cell Transplant Following Treatment
Fifth patient treated with CER-1236 underwent stem cell transplant following lack of response to prior therapies; Company initiates third planned cohort in ongoing Phase 1 study in hematologic malignancies SOUTH SAN FRANCISCO, Calif, June 15, 2026 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for CERO.
U.S. House Trading
No House trades found for CERO.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.